NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $2.13 +0.07 (+3.40%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Acrivon Therapeutics Stock (NASDAQ:ACRV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acrivon Therapeutics alerts:Sign Up Key Stats Today's Range$2.06▼$2.1450-Day Range$1.43▼$2.3952-Week Range$1.27▼$3.56Volume184,476 shsAverage Volume360,294 shsMarket Capitalization$91.27 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company Overview Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics. The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials. In parallel, Acrivon is advancing additional stapled-peptide programs directed at other oncogenic KRAS mutants such as G12D, with the goal of expanding its pipeline to address multiple unmet needs in solid tumor oncology. Acrivon was established in 2021 as a spin-out from Calibr, the drug discovery division of The Scripps Research Institute, and is headquartered in Redwood City, California. The company leverages its origin in academic research to maintain close collaborations with leading cancer centers and translational science groups across North America and Europe. Supported by a management team with extensive experience in biotechnology and pharmaceutical drug development, Acrivon is building strategic partnerships and advancing its peptide platform to potentially deliver first-in-class or best-in-class therapies for patients with RAS-mutant cancers. The company continues to focus on rigorous clinical development and regulatory engagement to bring novel peptide-based oncology treatments to market.AI Generated. May Contain Errors. Read More Acrivon Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreACRV MarketRank™: Acrivon Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 285th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingAcrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAcrivon Therapeutics has a consensus price target of $13.50, representing about 533.8% upside from its current price of $2.13.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Acrivon Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Acrivon Therapeutics are expected to grow in the coming year, from ($1.80) to ($1.47) per share.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Acrivon Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.22% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 4.05.Change versus previous monthShort interest in Acrivon Therapeutics has recently decreased by 8.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.73 News SentimentAcrivon Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acrivon Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,850.00 in company stock.Percentage Held by Insiders10.50% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acrivon Therapeutics' insider trading history. Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRV Stock News HeadlinesAcrivon Therapeutics to Present at the 2026 Cantor Global Healthcare ConferenceSeptember 2 at 8:00 AM | globenewswire.comAcrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business OfficerAugust 31, 2026 | globenewswire.comThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.September 4 at 1:00 AM | Behind the Markets (Ad)Peter Blume-Jensen Sells 14,036 Shares of Acrivon Therapeutics (NASDAQ:ACRV) StockAugust 28, 2026 | insidertrades.comAcrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data CatalystsAugust 13, 2026 | finance.yahoo.comAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyAugust 5, 2026 | globenewswire.comAcrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 ConferenceJuly 21, 2026 | globenewswire.comAcrivon Shareholders Approve Expanded Equity Plan and DirectorsJune 17, 2026 | tipranks.comSee More Headlines ACRV Stock Analysis - Frequently Asked Questions How have ACRV shares performed this year? Acrivon Therapeutics' stock was trading at $2.41 at the beginning of 2026. Since then, ACRV shares have decreased by 11.6% and is now trading at $2.13. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) issued its earnings results on Wednesday, August, 12th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.07. When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acrivon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings8/12/2026Today9/04/202612th Annual Cantor Fitzgerald Global Healthcare Conference9/09/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, ACRV's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACRV CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Price Target for Acrivon Therapeutics$13.50 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+533.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.14% Return on Assets-61.60% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book1.05Miscellaneous Outstanding Shares42,850,000Free Float38,353,000Market Cap$91.27 million OptionableNot Optionable Beta1.92 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ACRV) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredWall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts